Next-generation macrophages: repolarizing CAR-macrophages against cancer [0.03%]
下一代的巨噬细胞：用CAR分子极化巨噬细胞对抗癌症
Sima Ebrahimabadi,Dan S Kaufman
Sima Ebrahimabadi
Gut microbiota plays pivotal roles in benign and malignant hematopoiesis [0.03%]
肠道微生物群在良性及恶性血液病中起关键作用
Yuxuan Li,Biao Zhang,Lingli Jiang et al.
Yuxuan Li et al.
Accumulated evidence emerges that dynamic changes in human gut microbiota and microbial metabolites can alter the ecological balance of symbiotic hosts. The gut microbiota plays a role in various diseases through different mechanisms. More ...
Erythroferrone in focus: emerging perspectives in iron metabolism and hematopathologies [0.03%]
erythroferrone的研究热点：铁代谢和血液病理学的新观点
Sadia Babar,Muhammad Saboor
Sadia Babar
Beyond its core role in iron metabolism, erythroferrone (ERFE) has emerged as a key player with far-reaching implications in various hematologic disorders. Its regulatory effect on hepcidin underlines its significance in conditions characte...
New insights into the endothelial origin of hematopoietic system inspired by "TIF" approaches [0.03%]
基于“TIF”策略的造血系统内皮起源新见解
Siyuan Hou,Xia Guo,Junjie Du et al.
Siyuan Hou et al.
Hematopoietic stem progenitor cells (HSPCs) are derived from a specialized subset of endothelial cells named hemogenic endothelial cells (HECs) via a process of endothelial-to-hematopoietic transition during embryogenesis. Recently, with th...
Targeting HMGCS1 restores chemotherapy sensitivity in acute myeloid leukemia [0.03%]
靶向HMGCS1可恢复急性髓系白血病对化疗的敏感性
Cheng Zhou,Jue Li,Xiaofan Sun et al.
Cheng Zhou et al.
Acute myeloid leukemia (AML) is a common hematological malignancy with overall poor prognosis. Exploring novel targets is urgent and necessary to improve the clinical outcome of relapsed and refractory (RR) AML patients. Through clinical sp...
Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study [0.03%]
伊伏西達明治療中國復發/難治性異柠檬酸脫氫酶1突變急性髓系白血病患者：登記研究
Mingyuan Sun,Qingsong Yin,Yang Liang et al.
Mingyuan Sun et al.
Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor, has demonstrated clinical benefits in a pivotal study (AG120-C-001) in patients with IDH1-mutated (mIDH1) acute myeloid leukemia (AML). A registry study (CS3010-101: NCT04176393) w...
Xiaohuan Qin,Jiayi Lu,Peng Wu et al.
Xiaohuan Qin et al.
DNA methylation plays a critical role in hematopoietic differentiation. Epimutation is a stochastic variation in DNA methylation that induces epigenetic heterogeneity. However, the effects of epimutations on normal hematopoiesis and hematop...
Shuang Liu,Biao Chen
Shuang Liu
High percentage of bone marrow CD8+ tissue-resident-like memory T cells predicts inferior survival in patients with acute myeloid leukemia [0.03%]
急性髓系白血病患者骨髓类组织驻留型CD8+t细胞比例较高提示预后较差
Letong Cai,Wenpu Lai,Danlin Yao et al.
Letong Cai et al.
Tissue-resident memory T (TRM) cells infiltrating solid tumors could influence tumor progression and the response to immune therapies. However, the proportion and prognostic value of TRM cells in the bone marrow (BM) of patients with acute ...
Subcutaneous daratumumab in Chinese patients with relapsed or refractory multiple myeloma: an open-label, multicenter, phase 1 study (MMY1010) [0.03%]
来那度胺亚硝基脲联合方案治疗复发和难治多发性骨髓瘤的中国患者：Ⅰ期开放性、多中心临床试验（MMY1010）
Gang An,Zheng Ge,Hongmei Jing et al.
Gang An et al.
Despite recent progress in multiple myeloma (MM) treatments, most patients will relapse and require additional treatment. Intravenous daratumumab, a human IgGκ monoclonal antibody targeting CD38, has shown good efficacy in the treatment of...